Member Info for inanaco

to many just want to moan ... because they feel they called it wrong, indeed "Knowlesi short term play " "scancell"" has left him under water ..

rather amusing .. considering what he posts now ... "the Expert with a Loss" ....

what queue are you stuck in Crumbs ?

2 for the price of 1 "fish and Chips" .... at larry's .

people moan because life never quite fits into there expectations ...

? Request for MHRA Scientific Advice planned Q4 2019 as prelude to Clinical Trial
Application for First-in-Human study

anyway your all having a moan .. with No idea at all what is going on ....

so is this the Auditions for XMas, Scancells own Walking Bill Board Man ............ " the End of the world is Nigh"

Knowlesi ...

"""but it's not a play for those looking for short term returns.""""

what is .... ?

Lets have Knowlesi short term investment plays .....

i am so excited

I subscribe to the telegraph not the times otherwise i would do it .. Balerno thanks for the find .. if you have time, drop a note to the writer of that article, that this area of preserving long life has been harnessed by Scancell in the fight against cancer , and a Cytotoxic CD4 t cell vaccine has been produced with starling results in the mouse model

The more you look at that discovery ... that folks with high levels of Cytotoxic Cd4 t cells live past 100 years the more astonishing that Scancell has discovered the very T cell that does keep people clear of cancer in extreme old age

just think about that article ....................

in fact ... once cleared of cancer using Modi1 peptides the mouse model rejects any reestablishment of tumor

"memory" achieved

Supercentenarians .................. are Modi1 .. T cells

Nomlungu .... Bio Science Ltd

inventor of .... The sleeping pill you read ...

goodnight

except Ray spotted it ...

or they are confident enough to run a trial ...................

seems the obvious gets missed

By the way if you look at the "Quality" of that research ...

Immunotherapy Integrated Research Center, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle,

https://www.fredhutch.org/en/research/institutes-networks-ircs/immunotherapy-integrated-research-center.html

Ray Picked up on

""" many epithelial cancers lack class II MHC""""

Vimentin is a type III intermediate filament (IF) protein that is expressed in mesenchymal cells. ... Because of this, vimentin is often used as a marker of mesenchymally-derived cells or cells undergoing an epithelial-to-mesenchymal transition (EMT) during both normal development and metastatic progression.

modi1 has Two vimentin peptides

should read citrullinated and Homocitrulline ............. which Moditope targets

https://cancerimmunolres.aacrjournals.org/content/7/6/910

Scancell floods the cancer with "Th1 cytokine releasing T cells which promote MHC11 expression of Antigens specific to Moditope and homocittruline """"" target exposed ........... then the cytotoxic side of the CD4 kill those cells ...

so if it works ............. it will work fantastically well .... its a chain reaction

Adoptive transfer of human CD4+ T cells specific for a neoantigen resulted in a """""clinical response""""" in a patient with cholangiocarcinoma

this is in effect what BioNtech is doing with Scancell ... the only difference is we have the vaccine that does not need adoptive transfer

so BioNtech are looking at patients with compromised immune system or very late stage that require the potency of

"adoptive transfer" but adding in a "TCR" change followed by clonal expansion then returned to the patient ...

our science is correct ............ the effects of CD4 + T cells in patients that are responding is evidence enough of the importance of this area of the immune system

missing from investors ......... Patience

so unless you track the market for this very advanced science ... you would think "nothing is happening" .... when in reality Scancell is way ahead
we have a Neo Antigen CD4 vaccine ...........
we have CD4 TCR that works and i suggest the Mab 2811 developed by scancell plays a significant part in selection ...

the main bit is this ......... Th1 ..... "pro inflammatory"

Neoantigen vaccination strategies in murine models suggest that CD4+ responses to neoantigens are more prevalent and potentially more effective in antitumor immunity than CD8+ T-cell responses (15). A global analysis of immune subsets in a mouse model of tumor rejection highlighted changes in Th1 CD4+ T cells distant to the tumor, and showed the ability of adoptive transfer of these CD4+ T cells to confer antitumor immunity (14). Adoptive transfer of human CD4+ T cells specific for a neoantigen resulted in a clinical response in a patient with cholangiocarcinoma (28), and early results from neoantigen vaccination trials that elicited predominantly CD4+ T-cell responses support the clinical efficacy of these approaches (17, 40). Despite significant evidence pointing toward the importance of CD4+ T-cell responses to neoantigens, many epithelial cancers lack class II MHC, and the precise mechanisms through which CD4+ T cells mediate antitumor immunity remain to be fully elucidated.

Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 (Her2) Driver Mutations
Joshua R. Veatch, Brenda L. Jesernig, Julia Kargl, Matthew Fitzgibbon, Sylvia M. Lee, Christina Baik, Renato Martins, A. McGarry Houghton and Stanley R. Riddell
DOI: 10.1158/2326-6066.CIR-18-0402 Published June 2019

think is knowlesi you are not looking at other research that is highlighting the importance of "Neo Antigen TCR CD4 T cells"

We also report T-cell responses to driver mutations in lung cancer. The neoantigen created by the KRASG12V mutation recognized by the patients' CD4+ T cells is found in 4% of NSCLC, 10% of colorectal cancer, 30% of pancreas cancer, and 8% of ovarian cancer (8), and the HLA-DR11–restricting allele is found in 18% of patients (44). A second CD4+ T-cell response specific for the Her2 exon 20 insertion found in a different patient is present in 2% to 4% of NSCLC (9), and the HLA-DQ5–restricting allele is found in 30% of patients (44). Combined with our previous description of a BRAFV600E-specific CD4+ T-cell response in melanoma (27) and the work of others in different cancers (41, 45), these findings suggest that CD4+ T cells specific for recurrent driver mutations might be more common in human cancer than previously perceived. The finding that recurrent cancer mutations predicted to be presented to CD4+ T cells on class II MHC are underrepresented across multiple tumor types lends support to the hypothesis that driver mutation–specific CD4+ T cells could have a functional role in tumor surveillance (12).